About Sanjar Pharma Llp
Data last updated: 18 December 2025
Sanjar Pharma Llp is a limited liability partnership company based in Himatnagar, Gujarat, India, recognised as a startup by DPIIT. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 04 March 2014, the LLP has been in operation for over 12 years.
Registered with ROC Ahmedabad under LLPIN AAC-1431.
Capital: a total obligation of contribution of ₹4 Cr. It is led by designated partners Mohmadazaz Mohmadyunus Mukdiwala and Mohmadmoin Khalilahmed Modasiya.
Accounts filed on 31 March 2025. Office: L S No. 622/2/1/4 Dedhrota, Himatnagar, Gujarat, India – 383001.
As per the financials filed for FY 2024, the LLP reported a revenue of ₹18.75 Cr, a growth of 9.91% compared to the previous year.
The LLP has a workforce of approximately 15 employees as per the latest available data.
The LLP is associated with 1 brand - Sanjar Pharma. As per MCA filings, the LLP has open charges of ₹4.52 Cr and satisfied charges of ₹11 Cr on record.
For more details, the LLP can be reached via its website sanjarpharma.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressL S No. 622/2/1/4 Dedhrota, Himatnagar, Gujarat, India – 383001
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Sanjar Pharma Llp
Sanjar Pharma Llp operates one associated brand: Sanjar Pharma. These brands represent Sanjar Pharma Llp's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Injection manufacturing and pharmaceutical services in India. | sanjarpharma.com |
Designated Partners of Sanjar Pharma Llp
Sanjar Pharma Llp is currently managed by 2 designated partners, with 8 former designated partners having served the organization. The current Designated Partners play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Mohmadazaz Mohmadyunus Mukdiwala | Designated Partner | 04 Mar 2014 | 12 Years 4 Months | Current |
| Mohmadmoin Khalilahmed Modasiya | Designated Partner | 04 Mar 2014 | 12 Years 4 Months | Current |
Financials of Sanjar Pharma Llp FY 2025 filings available
Sanjar Pharma Llp reported revenue of ₹18.44 Cr (up 9.91% YoY) for FY 2024. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
View Sanjar Pharma Llp's control and ownership data: shareholding patterns, funding details, FII information, directors and KMP remuneration, group structure, overseas investment and related data.
-
Promoters: **.**%
-
Public: **.**%
-
Others: **.**%
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | |
|---|---|---|---|---|---|
| Promoters | **.** | **.** | **.** | **.** | **.** |
| Public | **.** | **.** | **.** | **.** | **.** |
| Others | **.** | **.** | **.** | **.** | **.** |
Full shareholding pattern with quarterly trends.
Charges & Borrowings of Sanjar Pharma Llp
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 May 2018 | Axis Bank Limited | ₹4.52 Cr | Open |
| 24 Nov 2015 | Dena Bank | ₹11 Cr | Satisfied |
Total charge records: 2 View all charges
Employees and EPFO Compliance at Sanjar Pharma Llp
Sanjar Pharma Llp has a workforce of 15 employees as of Mar 25, 2025.
Employee Count & EPFO Data of Sanjar Pharma Llp
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Sanjar Pharma Llp
GSTIN & GST Filing Data of Sanjar Pharma Llp
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Sanjar Pharma Llp
Credit Ratings, Legal Cases & Regulatory Alerts of Sanjar Pharma Llp
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Sanjar Pharma Llp
MSME Payment Delays by Sanjar Pharma Llp
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Sanjar Pharma Llp
Subsidiaries & Group Companies of Sanjar Pharma Llp
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Sanjar Pharma Llp with ownership details.
MCA Filings & Documents of Sanjar Pharma Llp
MCA Filings & Documents of Sanjar Pharma Llp
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Sanjar Pharma Llp
Frequently Asked Questions about Sanjar Pharma Llp
Sanjar Pharma Llp is an active limited liability partnership in the pharma sector based in Himatnagar, Gujarat, India. It was incorporated on 04 March 2014 (12+ years old) and is registered under LLPIN AAC-1431. The LLP has 15 employees.
Sanjar Pharma Llp reported revenue of ₹18.75 Cr for FY 2024 (up 9.91% YoY).
The current designated partners of Sanjar Pharma Llp are:
The primary industry of Sanjar Pharma Llp is pharma. The LLP specifically operates in drug formulation and development. The LLP is currently active in this sector.
Yes, Sanjar Pharma Llp is recognised as a startup by the Department for Promotion of Industry and Internal Trade (DPIIT).
Sanjar Pharma Llp can be reached at the registered office: L S No. 622214 Dedhrota, Himatnagar, Gujarat, India – 383001, or through the website sanjarpharma.com.